Related Experiment Videos
Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex
L Chang1, T Ernst, M Leonido-Yee
1Department of Neurology, University of California Los Angeles School of Medicine, Harbor-UCLA Medical Center, Torrance 90509, USA.
Objective:
To investigate the relation between biochemical alterations and disease severity in HIV-cognitive motor complex (HIV-CMC).
Background:
HIV-CMC encompasses both the milder form (HIV-minor cognitive motor disorder [HIV-MCMD]) and the more severe form (HIV-dementia). There is no validated marker to monitor disease severity noninvasively.
Methods:
A total of 54 patients with HIV-CMC (20 with HIV-MCMD, 34 with HIV-dementia) and 29 seronegative healthy volunteers were evaluated for cerebral metabolite abnormalities using proton (1H) MRS in the frontal cortex, frontal white matter, and basal ganglia.
Results:
The three subject groups showed different concentrations of myoinositol (MI; p = 0.0005) and choline-containing compounds (CHO; p = 0.004) in the frontal white matter. HIV-dementia patients had metabolite changes in all three brain regions whereas HIV-MCMD patients had abnormalities in the frontal white matter only. HIV-CMC patients had elevated MI (p < 0.0001) and CHO (p = 0.004) levels with increasing AIDS dementia complex stage, and N-acetyl compounds (NA) were decreased only in moderate to severe stages of dementia. Furthermore, CD4 count and CSF viral load, but not plasma viral load, showed significant effects on cerebral metabolite concentrations, which in turn showed significant effects on the HIV-dementia scale.
Conclusions:
In early stages of HIV-CMC, frontal white matter showed evidence of glial proliferation (with elevated MI and CHO levels) and cell membrane injury (with increased CHO levels), but no significant neuronal injury (with normal NA concentrations). HIV-MCMD and HIV-dementia patients have different neurochemical abnormalities. Because these biochemical alterations are related to clinical disease severity, they may be useful surrogate markers for noninvasive quantitative assessment of brain injury in patients with HIV-CMC.
Insights
Biochemical markers like myoinositol and choline show promise for assessing brain injury in HIV-CMC. These changes correlate with disease severity, offering potential noninvasive monitoring for HIV-MCMD and HIV-dementia.
Area of Science:
- Neuroscience
- Biochemistry
- Infectious Diseases
Background:
- HIV-cognitive motor complex (HIV-CMC) includes milder HIV-minor cognitive motor disorder (HIV-MCMD) and severe HIV-dementia.
- Currently, no validated noninvasive markers exist to monitor HIV-CMC disease progression.
- Understanding biochemical changes is crucial for managing HIV-associated neurological disorders.
Purpose of the Study:
- To investigate the relationship between biochemical alterations and disease severity in HIV-CMC.
- To identify potential noninvasive biomarkers for assessing brain injury in HIV-CMC patients.
Main Methods:
- Proton magnetic resonance spectroscopy (1H MRS) was used to evaluate cerebral metabolite concentrations.
- Studied 54 HIV-CMC patients (HIV-MCMD and HIV-dementia) and 29 healthy controls.
- Analyzed metabolites in the frontal cortex, frontal white matter, and basal ganglia.
Main Results:
- Significant differences in myoinositol (MI) and choline-containing compounds (CHO) were observed in frontal white matter across subject groups.
- HIV-dementia patients showed widespread metabolite abnormalities, while HIV-MCMD patients had changes primarily in frontal white matter.
- Elevated MI and CHO levels correlated with increased AIDS dementia complex stage; N-acetyl compounds (NA) decreased in moderate to severe stages.
Conclusions:
- Early HIV-CMC stages show glial proliferation and cell membrane injury, but not significant neuronal injury, in frontal white matter.
- Distinct neurochemical abnormalities differentiate HIV-MCMD from HIV-dementia.
- Biochemical alterations correlate with clinical disease severity, suggesting their utility as noninvasive surrogate markers for brain injury assessment in HIV-CMC.